Nalmefene HCl injection — Competitive Intelligence Brief

Nalmefene HCl injection (Nalmefene HCl injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor antagonist. Area: Addiction Medicine / Emergency Medicine.

marketed Opioid receptor antagonist Mu, delta, and kappa opioid receptors Addiction Medicine / Emergency Medicine Small molecule

Target snapshot

Nalmefene HCl injection (Nalmefene HCl injection) — Leiden University Medical Center. Nalmefene is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors with high affinity and specificity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nalmefene HCl injection TARGET	Nalmefene HCl injection	Leiden University Medical Center	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)
Naltrexone Tablet and Placebo Patch	Naltrexone Tablet and Placebo Patch	The Scripps Research Institute	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
naltrexone (Revia)	naltrexone (Revia)	University of North Carolina, Chapel Hill	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
MOVANTIK™ (naloxegol)	MOVANTIK™ (naloxegol)	Massachusetts General Hospital	marketed	Peripheral opioid receptor antagonist	Mu-opioid receptor (peripheral)
long-lasting injectable naltrexone	long-lasting injectable naltrexone	State University of New York - Upstate Medical University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
Naltrexone Pill	Naltrexone Pill	Albert Einstein Healthcare Network	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor antagonist class)

1. Albert Einstein Healthcare Network · 1 drug in this class
2. Cephalon · 1 drug in this class
3. Leiden University Medical Center · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. Paion UK Ltd. · 1 drug in this class
6. Pocket Naloxone Corp · 1 drug in this class
7. State University of New York - Upstate Medical University · 1 drug in this class
8. Texas Tech University · 1 drug in this class
9. The Scripps Research Institute · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class